Temat: lokivetmab - Katalog OPAC zbiorów

Skocz do pozycji: 1.

Tytuł:: Evaluation of the clinical efficiencyof lokivetmab in client privately ownedatopic dogs – multicenter study
Autorzy:: Szczepanik, M.P.
Popiel, J.
Cekiera, A.
Pomorska-Handwerker, D.
Karaś-Tęcza, J.
Ściskalska, M.
Oczkowska, K.
Taube, M.
Olender, V.
Parys, P.
Powiązania:: https://bibliotekanauki.pl/articles/2087319.pdf
Data publikacji:: 2020
Wydawca:: Polska Akademia Nauk. Czytelnia Czasopism PAN
Tematy:: atopic dermatitis
dog
lokivetmab
Źródło:: Polish Journal of Veterinary Sciences; 2020, 23, 2; 191-195
1505-1773
Pojawia się w:: Polish Journal of Veterinary Sciences
Dostawca treści:: Biblioteka Nauki

Artykuł

Zmień widok

na półce

Skocz do pozycji: 2.

Tytuł:: Correlation between clinical efficacy on pruritus and serum interleukin-31 levels in dogs with atopic dermatitis treated with lokivetmab
Autorzy:: Calesso, J.R.
Marques, V.S.
de Carvalho, O.V.
Costa-Val, A.P.
Powiązania:: https://bibliotekanauki.pl/articles/16647579.pdf
Data publikacji:: 2023
Wydawca:: Polska Akademia Nauk. Czasopisma i Monografie PAN
Tematy:: atopic dermatitis
interleukin-31
lokivetmab
monoclonal antibody
pruritus
Opis:: Studies on serum interleukin (IL)-31 levels in dogs with atopic dermatitis (AD) and their correlation with disease severity are limited. To the author’s knowledge, there are no studies that measured serum IL-31 in dogs treated with lokivetmab injections, a selective inhibitor of this key cytokine in pruritus. The aim of the study was to evaluate serum IL-31 levels in dogs treated with lokivetmab and correlate it with the severity of canine atopic dermatitis using the pruritus visual analog scale (pVAS) and canine atopic dermatitis extent and severity index (CADESI-04). Ten client-owned dogs diagnosed with AD received two injections of lokivetmab four weeks apart. Disease severity was assessed using the pVAS and CADESI-04 scores before and after both injections. In addition, canine serum IL-31 levels were measured at the same moments. Serum IL-31 was detected in all dogs in the study. There was a significant reduction in pVAS scores and serum IL-31 after administrations. However, there was no difference in CADESI-04 scores, and there was no significant correlation between CADESI-04 scores and serum IL-31 in dogs diagnosed with AD. Nonetheless, a significant positive correlation was observed between the pVAS scores and serum IL-31 levels with lokivetmab therapy, which reinforces the role of IL-31 in the pathogenesis of pruritus in dogs with AD. The data presented here provide further evidence that IL-31 is directly involved in pruritus pathogenesis in dogs with AD. In addition, blocking IL-31 has a significant antipruritic effect, but has no influence on skin lesion severity and extension.
Źródło:: Polish Journal of Veterinary Sciences; 2023, 26, 2; 231-238
1505-1773
Pojawia się w:: Polish Journal of Veterinary Sciences
Dostawca treści:: Biblioteka Nauki

Artykuł

Zmień widok

na półce

Informacja

Wyszukujesz frazę "lokivetmab" wg kryterium: Temat

Źródło danych

Dostawca treści

Kolekcja

Rok wydania

Wydawca

Temat

Autor

Typ dokumentu

Język